RET and hepatocellular carcinoma: Given that ARTN stimulated cellular function is also RET-independent, the preferred approach to inhibit ARTN function in HCC would be by targeting the ligand itself, for example, as achieved with the neutralizing monoclonal antibody Bevacizumab for VEGFA, which also binds multiple receptors [42].